Canadian pharmaceutical company Apotex is to alter its structure with the aim of improving customer service and will now operate along three core lines of business.
Global Generics will be responsible for the delivery of the generics portfolio; Global Speciality Pharma will handle the development, manufacturing and global commercialisation of biosimilars and other speciality products; and Global Active Pharmaceutical Ingredients (API) will deliver APIs to the Apotex Group and handle sales of selected APIs to other global customers.
Jeff Watson, currently President of US & Canada Commercial, will head Global Generics as President; Steve Lydeamore, currently Chief Business Officer and Managing Director International, will become President Global Speciality Pharma; while Keshava Murthy will continue in his role of President Global API.
'The three principal objectives with this new model are to focus all of Apotex on a core strategy – aligned with our global customers, improve our capabilities in all disciplines and areas, and work together with greater collaboration and agility around common goals,' said Jeremy Desai, President and CEO.
He expects these changes will create a 'higher performance-driven Apotex with improved customer focus', which is 'better able to capitalise on emerging opportunities in our rapidly evolving industry'.
Apotex employs more than 10,000 people globally and has estimated sales of approximately US$2bn. With its worldwide manufacturing sites, the company can produce up to 24 billion dosage forms each year.